Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Maria R. Baer"'
Autor:
Deepa Jeyakumar, Ryan D. Cassaday, Roch Houot, Chaoling Feng, Dimitrios Tzachanis, Maria R. Baer, John M. Rossi, Patrick J. Stiff, Marion Subklewe, Max S. Topp, Behzad Kharabi Masouleh, Bijal D. Shah, Remus Vezan, Martha Arellano, Olalekan O. Oluwole, Aaron C Logan, William G. Wierda, Kristen M. O'Dwyer, Tong Shen, Monique C. Minnema, Jinghui Dong, Daniel J. DeAngelo, Nicolas Boissel, Mehrdad Abedi, Francesca Milletti, Gary J. Schiller, Thibaut Leguay, Armin Ghobadi, Michael R. Bishop, Yi Lin, Jae H. Park
Publikováno v:
Lancet
Lancet, Elsevier, 2021, 398 (10299), pp.491-502. ⟨10.1016/S0140-6736(21)01222-8⟩
The Lancet
The Lancet, 2021, 398 (10299), pp.491-502. ⟨10.1016/S0140-6736(21)01222-8⟩
Lancet, Elsevier, 2021, 398 (10299), pp.491-502. ⟨10.1016/S0140-6736(21)01222-8⟩
The Lancet
The Lancet, 2021, 398 (10299), pp.491-502. ⟨10.1016/S0140-6736(21)01222-8⟩
International audience; BACKGROUND: Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT) consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia remain poor, und
Autor:
Jonathan Cornu, Vu H. Duong, Alison Duffy, Maria R. Baer, Sandrine Niyongere, Jummai Apata, Ciera L Patzke, Noa G. Holtzman, Sarah M. Kashanian, Ashkan Emadi, Farin Kamangar, Madhurima Koka
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:817-826
Asparaginases, key agents in treatment of acute lymphoblastic leukemia (ALL), are associated with venous thromboembolism (VTE). While risks of short-acting asparaginase-related VTE is well-known, we studied VTE incidence and risk factors in adult ALL
Autor:
Rena G. Lapidus, Jaya Sangodkar, Christopher Bailey, Danilo Perrotti, Maria R. Baer, Shivani Kapoor, Mario Scarpa, Yin Wang, Prerna Singh, Goutham Narla, Sandrine Niyongere, Jonelle K. Lee
Publikováno v:
Mol Cancer Ther
Fms-like tyrosine-like kinase 3 internal tandem duplication (FLT3-ITD) is present in acute myeloid leukemia (AML) in 30% of patients and is associated with short disease-free survival. FLT3 inhibitor efficacy is limited and transient but may be enhan
Autor:
Yang Liu, Sami N. Malek, Brian Parkin, Yin Wang, Duxin Sun, Miao He, Yan Liu, Maria R. Baer, Peng Zhang, Pan Zheng, Huixia Zhang, Christopher Bailey
Publikováno v:
Oncogene
TP53 mutation in acute myeloid leukemia (AML) is associated with poor prognosis. Since no targeted therapy is available to restore p53 function, it is of great interest to test whether other pathways activated by TP53 mutations can be therapeutically
Autor:
Geoffrey L. Uy, Maria R. Baer, Wendy Stock, Weiqiang Zhao, Ellen K. Ritchie, Richard A. Larson, Jennifer Le-Rademacher, Heidi D. Klepin, Richard Stone, Susan A. Geyer, Ben L. Sanford, Karla V. Ballman, Drew K. Seisler, Libby Storrick, Bayard L. Powell, Guido Marcucci, Brittny Major-Elechi, Harvey J. Cohen
Publikováno v:
J Geriatr Oncol
Objective To demonstrate feasibility of performing geriatric assessment (GA) in the National Clinical Trials Network (NCTN) and to explore the utility of GA to characterize treatment tolerance. Materials and methods We conducted a multisite companion
Autor:
Robert K. Stuart, Je-Hwan Lee, Andreas Neubauer, Jorge E. Cortes, Richard A. Larson, Timothy S. Pardee, Mark J. Levis, Chaofeng Liu, Harry P. Erba, Sung Soo Yoon, Celalettin Ustun, Ellin Berman, Maria R. Baer, Nikolai A. Podoltsev, Wen-Chien Chou, Giovanni Martinelli, Nahla Hasabou, Pau Montesinos, Antonio Di Stasi, Stefania Paolini, Alexander E. Perl, Francesco Fabbiano, Hisayuki Yokoyama, Xuan Liu, Margaret Kasner, Rebecca L. Olin, Naoko Hosono, Erkut Bahceci, Amir T. Fathi, Fabio Ciceri, Christian Recher
Publikováno v:
NEW ENGLAND JOURNAL OF MEDICINE
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
BACKGROUND Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to salvage chemotherapy. Gilteritinib is an oral, potent, selective FLT3 inhibitor
Publikováno v:
Leukemia & Lymphoma. 62:1275-1277
Hereditary breast cancer is caused by autosomal dominant germline mutations in human breast cancer genes, mainly BRCA1 and BRCA2. BRCA mutations are associated with increased risk of breast and ova...
Autor:
Eric A. Gehrie, Maria R. Baer, Gabriel Ghiaur, Kyle Zacholski, Ivana Gojo, Amy E. DeZern, Matthew J Newman, Ashkan Emadi, Sarah M. Kashanian, B. Douglas Smith, Andrew Y. Li, Ravi Varadhan, Erin Hickey, Bryan C. Hambley, Mark J. Levis, Vu H. Duong
Publikováno v:
J Oncol Pharm Pract
Arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) combination therapy yields high complete remission and disease-free survival rates in acute promyelocytic leukemia (APL). ATO is dosed on actual body weight and high ATO doses in overweight pa
Autor:
Uwe Platzbecker, Maria R. Baer, Benedikt Brors, Zuzana Šustková, Richard F. Schlenk, Tomáš Szotkowski, Pavel Zak, Carsten Müller-Tidow, Gregor Warsow, Francesca Guijarro, Sabine Kayser, Alan Kenneth Burnett, Angela Schulz, Mark J. Levis, Roland B. Walter, Carole Shaw, David Grimwade, Jordi Esteve, Christoph Röllig, Gerhard Ehninger, Christian Thiede, Elihu H. Estey, Petr Cetkovsky, Andrew M. Brunner, Anthony D. Ho, Robert Kerrin Hills, Ralitsa Langova, Nigel H. Russell, Zdeněk Ráčil, Michael Kramer, Jiri Mayer
In acute myeloid leukaemia (AML) t(8;16)(p11;p13)/MYST3-CREBBP is a very rare abnormality. Previous small series suggested poor outcome. We report on 59 patients with t(8;16) within an international, collaborative study. Median age was 52 (range: 16-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff05dfb4c0cfe20e3c626f735710e68a
Autor:
Maria R. Baer, Noa G. Holtzman, Gabriel Ghiaur, Firas El Chaer, Amy E. DeZern, Ivana Gojo, Bryan C. Hambley, Kyle Zacholski, Ashkan Emadi, Vu H. Duong, Sarah M. Kashanian, Kelly J. Norsworthy, Andrew Y. Li, B D Smith, Jonathan Webster, Farin Kamangar, Mark J. Levis
Publikováno v:
Biology
Biology, Vol 10, Iss 243, p 243 (2021)
Biology, Vol 10, Iss 243, p 243 (2021)
Simple Summary Around 12–38% of acute promyelocytic leukemia (APL) patients carry the FLT3-ITD mutation, which has been associated with several poor-prognosis indicators such as high white blood cell counts, M3v variant morphology, and the bcr3 iso